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Summary A 74-year-old woman was admitted to our hospital with chest pain and short-
ness of breath. Coronary arteriograms revealed occlusion of a drug-eluting stent, which had
been implanted 33 months earlier, in the middle right coronary artery. During percutaneous
coronary intervention, distal embolization developed and a thrombus was detected with an
aspiration catheter. Serological examinations performed 1 year before and during the presentDrug-eluting stent hospitalization revealed positive lupus anticoagulant activity. Thrombophilic tendencies, such
as antiphospholipid syndrome, are noteworthy as one of the causative factors in very late stent
thrombosis.
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t has been recently demonstrated that stent thrombo-
is may occur more than a year after implantation of a
rug-eluting stent (DES). It has also been reported that
iscontinuation of antiplatelet therapy and procedural and
esion-related variables, such as stent underexpansion, stent
ength, and multivessel disease, are risk factors for stent
hrombosis. Among patient-related variables, diabetes mel-
itus and renal failure have been mentioned as risk factors
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1]. However, despite being a thrombotic complication,
hrombophilic tendencies are discussed in few reports. Here
e present a case of very late stent thrombosis after implan-
ation of DESs in a patient with antiphospholipid syndrome
APS).
ase report
74-year-old woman was admitted to our hospital with
hest pain and shortness of breath, which had developed
weeks earlier. She had undergone percutaneous coronary
ntervention 33 months before the present hospitalization
or effort angina. Sirolimus-eluting stents had been suc-
essfully implanted in the middle and distal right coronary
rtery (segments 2 and 3 in Fig. 1). Four months after
Published by Elsevier Ireland Ltd. All rights reserved.
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aFigure 1 Coronary arteriograms obtained 33 months before st
the right coronary artery (a), and successful implantation of sir
stenting, coronary arteriograms showed no restenosis. One
year before the present hospitalization, she had visited the
outpatient department of neurology in our hospital because
of dizziness. Prolonged activated partial thromboplastin
time, positive lupus anticoagulant activity, and lacunar
stroke had been detected.
Routine hematological and blood chemistry tests on
admission, including platelet count, were normal. Left
coronary arteriograms did not show stenosis but showed col-
lateral circulation to the right coronary artery with no ﬁlling
defect of the contrast medium in the stent implanted at seg-
ment 3 (Fig. 2a). The right coronary arteriogram revealed an
in-stent obstruction at segment 2 (Fig. 2b).
Dual antiplatelet therapy consisting of aspirin
(81mg/day) and ticlopidine (200mg/day) was continued
after stenting. As mentioned above, lupus anticoagulant
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Figure 2 Retrograde right coronary arteriogram through collateral
the contrast medium in the stent implanted at segment 3 (white arrow
in the stent implanted at segment 2 (b). After balloon dilation, the
recognized as a ﬁlling defect in the stent implanted at segment 3 (bl
therapy of the thrombus.hrombosis. Severe stenosis can be seen at segments 2 and 3 of
s-eluting stents has been accomplished (b).
as detected 1 year previously and serological examination
evealed positive lupus anticoagulant activity again (67.5 s)
Table 1). The activated partial thromboplastin time was
easured using Thrombocheck APTT-SLA (Sysmex Corpo-
ation, Kobe, Japan). The presence of lupus anticoagulant
as conﬁrmed from the difference between the coagulation
ime after addition of normal plasma and that after addition
f excess phospholipid by the phospholipid neutralization
ssay using STACLOT L.A. (BML. Inc. Tokyo, Japan).
Warfarin was then added to the dual antiplatelet ther-
py, and the patient underwent coronary intervention 5 days
fter routine coronary catheterization. The lesion was eas-
ly crossed using a ﬂoppy guide-wire and a balloon. However,
fter balloon deﬂation, a right distal coronary arteriogram,
btained through a micro catheter inserted deeply into
he right coronary artery, revealed a ﬁlling defect in the
vessels from the left coronary artery shows no ﬁlling defect of
in panel a). The right coronary arteriogram reveals obstruction
right coronary arteriogram shows distal embolization which is
ack arrow in panel c). (d) The ﬁnal arteriogram after aspiration
e118 T. Hondo et al.
Table 1 Results of serological tests.
Reference values One year earlier Day 3
C3 80—140mg/dl 120
C4 11—34mg/dl 40.8
CH50 30—45U/ml 60
Anti-nuclear antibody 0—79 <40
Protein C 70—150% 129
Protein C activity 70—140% 131
Protein S 65—135% 95
Anti-CL.2GP1 antibody ∼3.5U/ml 1.7
IgG anticardiolipin antibody ∼10U/ml 9
Lupus anticoagulants 0—7.9 s 78.4 67.5
PT (s) 10—12 s
PT (%) 70—150% 120
APTT (s) 25—35 s 60.5
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Fib 200—400mg/d
tent implanted at segment 3 (Fig. 2c). This ﬁlling defect
ad not been recognized in the retrograde arteriogram
btained through the collateral circulation at routine coro-
ary catheterization. We conﬁrmed the presence of a
hrombus using an aspiration catheter and diagnosed drift-
ng of the thrombus which occluded segment 2 resulting in
mbolization at segment 3. There was no stent fracture, and
ncomplete stent apposition was not detected by intravas-
ular ultrasonography. The atrioventricular node artery was
eperfused but the posterior descending artery remained
ccluded after aspiration of the thrombus and adminis-
ration of isosorbide dinitrate, nicorandil, and verapamil
ydrochloride (Fig. 2d). However, there was a collateral
irculation from the left coronary artery to the posterior
escending artery, and hence, partial resolution of ST ele-
ation was noted and coronary intervention came to an end.
he clinical course was good and recurrence of stent throm-
osis was not recognized. The patient was discharged on day
1.
iscussion
ate stent thrombosis after DES implantation has recently
eceived a great deal of attention. In general, risk factors
or stent thrombosis include discontinuation of antiplatelet
herapy and procedure-related variables such as stent
nderexpansion, stent length, and the presence of multives-
el disease. Incomplete endothelialization, hypersensitivity
eactions to DES polymer, and incomplete stent apposition
ave also been mentioned as pathological factors [1].
Among clinical variables, diabetes mellitus and renal fail-
re are generally suggested as risk factors. However, there
re few reports concerning thrombophilic tendencies in rela-
ion to stent thrombosis. Acar et al. [2] reported a case
f acute stent thrombosis related to the deﬁciency of pro-
ein C and protein S. Turgut et al. [3] described a case of
tent thrombosis 48 h after bare-metal stent implantation
ssociated with essential thrombocythemia.
APS [4] is characterized by the presence of antiphos-
holipid antibodies (aPL), such as lupus anticoagulant (LA),
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nticardiolipin antibody (aCL), and anti-2 glycoprotein I
ntibody, along with at least one clinical manifestation, such
s arterial or venous thrombosis, or complications related to
regnancy. Cerebral and myocardial infarctions are common
n patients with arterial thrombosis, which occurs less fre-
uently than venous thrombosis. Several mechanisms have
een proposed to explain the prothrombotic condition in
PS, including inhibition of protein C activation, inhibition
f antithrombin, activation of platelets, interaction with
ndothelial cells resulting in tissue factor upregulation, and
ctivation of the complement pathway by aPL.
In the Antiphospholipid Antibodies and Stroke Study
APASS) [5], 1770 patients who had experienced an ischemic
troke within 30 days were classiﬁed as positive or nega-
ive for aPL (either LA or aCL). The presence of aPL was not
ssociated with subsequent vascular occlusive events over
years. However, a small subgroup in this study suggested
hat those who test positive for both LA and aCL antibod-
es tend to have a higher event rate. Zuckerman et al. [6]
ound a high level of aCL in 17 (14%) of 124 patients with
cute myocardial infarction (aged 65 years or younger) on
dmission, and with the exception of one case, these lev-
ls persisted 3 months after the infarction. They concluded
hat the presence of aCL was a marker for a high risk of
ecurrence of coronary and thromboembolic events. Greco
t al. [7] reported that 86 (37%) of 232 patients with chest
ain syndromes and acute coronary events were positive
or one or more aPL, and the presence of aPL was associ-
ted with the subsequent clinical course. They also reported
hat a family history of APS-related events was frequently
ssociated with aPL positivity in patients. Serological tests,
ncluding aPLs, might be needed before percutaneous coro-
ary intervention in such cases.
There have been reports of cases in which stents were
uccessfully placed in patients with APS presenting with
cute myocardial infarction or angina pectoris [8,9]. How-
ver, stent thrombosis occurred in some cases [10—14]. Ito et
l. [10] reported a case of acute myocardial infarction con-
urrent with primary antiphospholipid syndrome, in which
tent thrombosis occurred after emergency bare-metal
tenting. After a routine catheterization with intravascular
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ultrasound examination, thrombosis recurred in the chronic
phase. Su et al. [11] described acute stent thrombosis after
elective stenting in a patient with angina pectoris accom-
panied by APS. Muir et al. [12] also reported a case of
recurrent acute stent thrombosis in APS secondary to renal
cell carcinoma. Kyoi et al. [13] described a case of APS
with very late stent thrombosis 7 years after bare-metal
stent implantation. They indicated that multiple factors,
such as discontinuation of antiplatelet therapy and dehy-
dration induced by exercise, overlapped with disturbed
re-endothelialization or malposition due to certain pre-
existing causes, promoted the thrombogenicity in APS.
There are few reports of stent thrombosis after DES
implantation in APS. Weissman and Coplan [14] described
recurrent acute stent thrombosis after coronary interven-
tion. In their case, coronary artery bypass graft surgery was
eventually required. To our knowledge, there is no report
of very late stent thrombosis after DES implantation in a
patient with APS.
In the present case we diagnosed the patient as having
APS because she suffered lacunar stroke and very late stent
thrombosis, and had positive lupus anticoagulant activity
that was measured 1 year before and during this hospital-
ization. Although this patient had a prothrombotic condition
concurrent with APS, the trigger for stent thrombosis was
unknown. Dual antiplatelet therapy was continued and there
was no evidence of dehydration, infectious disease, or
injury. There was no stent fracture, and incomplete stent
apposition was not detected by intravascular ultrasonogra-
phy. However, the presence of a thrombus was clear from the
occurrence of distal embolization as well as from aspirated
materials. Other factors such as chronic local inﬂammation
may have gradually promoted APS thrombogenicity and an
occluded thrombus might have been formed in the absence
of myocardial infarction.
Standard oral treatment after PCI in patients with APS
has not been established. In the APASS [5], there was no
differential response to warfarin and aspirin therapy. How-
ever, in the present case, because the thrombotic occlusion
occurred despite continuation of dual antiplatelet therapy,
we considered that warfarin was needed in addition to dual
antiplatelet therapy.
In conclusion, very late stent thrombosis may be associ-
ated with multiple factors. Thrombophilic tendencies such
as APS should be considered as one of the causative factors
of stent thrombosis.References
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